Dailypharm Live Search Close

Asthma drug 'Monterizine' sales rise despite generic entries

By Kim, Jin-Gu | translator Hong, Ji Yeon

24.11.12 05:59:08

가나다라 0
KRW 3.7B→KRW 4.3B in a year…Monterizine Chewable Tab is the only available treatment for young children

The drug price has been maintained despite generic listing in October 2023…original-generic "different formulation"

Hanmi's asthma treatment, 'Monterizine,' successfully expanded its prescription sales over 10% Year-over-Year (YoY), despite the release of generics.

Generic drugs had been listed for reimbursement in October 2023. The analysis suggests that Monterizine's continued sales expansion is because generic prices have not been reduced and, it maintains a strong market presence with its broader scope of use.

Prescription sales 14%↑despite generic releases… Monterizine Chewable Tab is the only available treatment for young children

According to the pharmaceutical market research firm UBIST on November 8, Hanmi's Monterizine recorded prescription sales of KRW 4.3 billion in Q3,

Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)